Rhenman & Partners Asset Management’s Oruka Therapeutics ORKA Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.61M	Buy	+80,000	New	+$5.33M	0.72%	57

Other funds holding ORKA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Rhenman & Partners Asset Management's ORKA Position: Q2 2026 in Review

Rhenman & Partners Asset Management opened a new position in Oruka Therapeutics (ORKA) in Q2 2026: 80,000 shares worth $7.61M. The stake represents 0.72% of the portfolio and ranks #57 among its holdings.

255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

Rhenman & Partners Asset Management held 80,000 shares of Oruka Therapeutics worth $7.61M as of Q2 2026.
Oruka Therapeutics was a new Rhenman & Partners Asset Management position in Q2 2026.
Oruka Therapeutics made up 0.72% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #57 holding.
255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.